Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019209 (
hepatomegaly
)
5,798
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Selenoneine is a novel organic selenium compound markedly found in the blood, muscles, and other tissues of fish. This study aimed to determine whether selenoneine attenuates hepatocellular injury and hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). Mice lacking farnesoid X receptor (FXR) were used as a model for fatty liver disease, because they exhibited
hepatomegaly
, hepatic steatosis, and hepatic inflammation.
Fxr
-null mice were fed a 0.3 mg Se/kg selenoneine-containing diet for four months. Significant decreases in the levels of
hepatomegaly
, hepatic damage-associated diagnostic markers, hepatic triglycerides, and total bile acids were found in
Fxr
-null mice fed with a selenoneine-rich diet. Hepatic and blood clot total selenium concentrations were 1.7 and 1.9 times higher in the selenoneine group than in the control group. A marked accumulation of selenoneine was found in the liver and blood clot of the selenoneine group. The expression levels of oxidative stress-related genes (
heme oxygenase 1
(
Hmox1
),
glutathione S-transferase alpha 1
(
Gsta1
), and
Gsta2
), fatty acid synthetic genes (
stearoyl CoA desaturase 1
(
Scd1
) and
acetyl-CoA carboxylase 1
(
Acc1
)), and selenoprotein (
glutathione peroxidase 1
(
Gpx1
) and
selenoprotein P
(
Selenop
)) were significantly decreased in the selenoneine group. These results suggest that selenoneine attenuates hepatic steatosis and hepatocellular injury in an NAFLD mouse model.
...
PMID:Selenoneine Ameliorates Hepatocellular Injury and Hepatic Steatosis in a Mouse Model of NAFLD. 3260 60
